TGF-β
A multifunctional cytokine involved in cell growth, differentiation, immune regulation, and other cellular processes.
PRODUCT DETAILS / RESEARCH USE ONLY
SOLUTION C19-MC™
Placenta-Derived Extracellular Vesicles for Research
A placenta-derived exosome preparation developed for advanced life science research. This page brings together biological context, characterization observations, sourcing, processing, and product specifications.
Placenta-DerivedMade in JapanRUO in North America
02 / BIOLOGICAL ORIGIN
Human Placenta. A Distinctive Origin.
Human placenta is a highly specialized organ studied for its extracellular vesicles and regulatory microRNAs. SOLUTION C19-MC™ uses human placental source material provided by Japan Bio Products Co., Ltd. (JBP).
The scientific context of placental EVs is distinct from the characterization observations made with this specific product.
03 / MOLECULAR CHARACTERISTICS
The C19MC miRNA Cluster
C19MC is a large, placenta-associated microRNA gene cluster on chromosome 19. C19MC miRNAs have been identified in extracellular vesicles released by placental trophoblasts.
These statements describe published placental biology. They do not, by themselves, establish the quantity or activity of individual C19MC miRNAs in SOLUTION C19-MC™.
04 / CHARACTERIZATION DATA
TOM20: A Window into Mitochondrial Biology
TOM20 is a receptor component of the mitochondrial outer-membrane protein import machinery and is widely used as a marker associated with mitochondrial abundance or status. The following values represent relative TOM20 levels reported under the indicated evaluation conditions.
Relative TOM20 level Control = 1.0
Relative values from the supplied evaluation summary. Assay details and statistical significance are not provided here.
About Curacen
Curacen is a human placenta-derived extract preparation from Japan Bio Products (JBP). It was included as a comparator in this TOM20 assessment. Curacen and SOLUTION C19-MC™ are distinct preparations and should not be regarded as compositionally equivalent.
Observation
Higher relative TOM20 levels were observed in the C19-MC and combination conditions than in control.
Biological Context
TOM20 is associated with mitochondrial protein import and is used in mitochondrial biology research.
Interpretation
The observed changes may reflect mitochondrial abundance or status. These results do not independently demonstrate improved mitochondrial function, mitophagy, or clinical benefit.
VEGF
A signaling protein involved in vascular biology and endothelial cell responses.
Selected biological factors, including TGF-β and VEGF, were measured during the evaluation. Quantitative results are not presented on this page.
05 / PROCESS & QUALITY
Controlled Processing in Japan
SOLUTION C19-MC™ brings together Japanese placental sourcing and culture/cell-processing performed by ONODERA Medical.
- Placental Source MaterialProvided by JBP
- Culture / Cell ProcessingONODERA Medical, Japan
- Purification & Quality ManagementControlled process
- Frozen StorageControlled frozen handling
- SOLUTION C19-MC™Research-use product
06 / SAFETY TESTING
Safety and Quality Management
According to the supplied JBP evaluation materials, testing of human placental tissue and placenta-derived cells reported negative results for the listed viral targets.
Culture / cell processing is carried out by ONODERA Medical in Japan. The ONODERA Medical CPC is in Otemachi, Tokyo (facility number FA3220004).
Reported viral targets
HIV-1HIV-2HBVHCVHTLVParvovirus B19
Reported result: Negative for the listed targets.
Source: Japan Bio Products Co., Ltd. Supplied product evaluation materials. This is not a claim of comprehensive pathogen absence or ICH Q5A compliance.07 / PRODUCT SPECIFICATIONS
Product Information
ProductSOLUTION C19-MC™
Biological originHuman placenta-derived
FormatLiquid (frozen)
Package1 mL × 5 vials / box
Storage−80°C to −20°C
Country of manufactureJapan
Distributor / inquiriesNodegraf Co., Ltd.
Intended useResearch Use Only (RUO) in North America
08 / REFERENCES
Scientific References
These publications provide general scientific context for placental extracellular vesicles and C19MC biology; they are not independent validation of SOLUTION C19-MC™ performance.
- Donker RB et al. (2012). The expression profile of C19MC microRNAs in primary human trophoblast cells and exosomes. View publication ↗
- Delorme-Axford E et al. (2013). Human placental trophoblasts confer viral resistance to recipient cells. View publication ↗
- Welsh JA et al. (2024). Minimal information for studies of extracellular vesicles (MISEV2023). View publication ↗
09 / DOCUMENTATION
Technical Documentation
For information about the availability of additional technical documentation, please contact Nodegraf.
Product information / technical inquiriesinfo@nodegraf.com ↗
CONTACT
Let’s Explore
What’s Next in Research.
For product information, research-use inquiries, purchasing, or distribution inquiries, please contact us.
✉ info@nodegraf.com